Holen Sie sich die Stockscreener-App
7.32
0.27%
0.02
Schlusskurs vom Vortag:
$7.30
Offen:
$7.3
24-Stunden-Volumen:
1.42M
Relative Volume:
0.74
Marktkapitalisierung:
$2.29B
Einnahmen:
$2.68B
Nettoeinkommen (Verlust:
$-184.45M
KGV:
-10.76
EPS:
-0.6805
Netto-Cashflow:
$229.23M
1W Leistung:
+2.23%
1M Leistung:
-5.55%
6M Leistung:
-11.49%
1J Leistung:
+7.96%
1-Tages-Spanne:
$7.19
$7.385
1-Wochen-Bereich:
$7.19
$7.385
52-Wochen-Spanne:
$6.29
$9.475
Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile
Firmenname
Amneal Pharmaceuticals Inc
Sektor
Telefon
908-947-3120
Adresse
400 Crossing Boulevard, 3rd Floor, Bridgewater
Vergleichen Sie AMRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMRX
Amneal Pharmaceuticals Inc
|
7.32 | 2.24B | 2.68B | -184.45M | 229.23M | -0.6805 |
|
HLN
Haleon Plc Adr
|
11.35 | 50.14B | 14.35B | 1.85B | 0 | 0.4023 |
|
ZTS
Zoetis Inc
|
168.63 | 72.38B | 9.29B | 2.52B | 2.28B | 5.57 |
|
RDHL
Redhill Biopharma Ltd Adr
|
1.79 | 4.22M | 35.75M | 11.57M | -26.25M | -3.8069 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.03 | 45.51B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.78 | 19.45B | 16.54B | -1.64B | 749.00M | -1.45 |
Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-24 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-09-06 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-03-08 | Hochstufung | Goldman | Sell → Buy |
| 2020-12-14 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-12-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-07-27 | Eingeleitet | Goldman | Sell |
| 2020-05-12 | Hochstufung | Guggenheim | Sell → Neutral |
| 2019-12-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-11-12 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2019-11-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2019-07-22 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-07-11 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-07-08 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-21 | Hochstufung | Raymond James | Mkt Perform → Strong Buy |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2019-03-08 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2018-12-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-10-16 | Herabstufung | SunTrust | Buy → Hold |
| 2018-08-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-07-23 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-06-22 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Amneal Pharmaceuticals Inc Aktie (AMRX) Neueste Nachrichten
Amneal to Participate at Upcoming Investor Conferences in June - GlobeNewswire
Amneal CEO and CFO Set for Exclusive Presentations at Two Major Healthcare Investor Conferences - Stock Titan
Bank of America Corp DE Has $4.41 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
FDA approves Amneal’s DHE migraine/cluster headache autoinjector - MSN
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $716,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Pharyngitis Treatment Market with Antibiotics and Home - openPR.com
3 Reasons Growth Investors Will Love Amneal (AMRX) - Yahoo Finance
Deutsche Bank AG Has $1.06 Million Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Hydroxychloroquine Market to Witness Remarkable Growth with - openPR.com
Insider Sell: Nikita Shah Sells Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus
Migraine Market Enters New Era Following Satsuma Pharmaceuticals' ATZUMI and Amneal Pharmaceuticals' BREKIYA Regulatory Approval | DelveInsight - PR Newswire
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by BNP Paribas Financial Markets - Defense World
Ameriprise Financial Inc. Sells 49,121 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal gets U.S. FDA nod for Brekiya as a migraine treatment - MSN
US FDA approves Amneal's self-administered migraine treatment - Reuters
AMRX Q1 Earnings Call: Miss on Revenue, Margin Expansion, and Product Pipeline Progress - Yahoo Finance
Amneal Gets FDA Nod For Self-Administrable Migraine Injection - MSN
The Manufacturers Life Insurance Company Has $689,000 Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal gets FDA approval for Brekiya to treat migraine and cluster headaches - World Pharmaceutical Frontiers
Amneal’s Brekiya autoinjector approved by FDA for migraines - Investing.com Nigeria
Northern Trust Corp Purchases 156,699 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World
Amneal’s Brekiya autoinjector approved by FDA for migraines By Investing.com - Investing.com South Africa
Amneal Gets FDA Nod For Self-Administrable Migraine Injection By Stocktwits - Investing.com India
FDA Approves Amneal's (AMRX) Brekiya Autoinjector for Migraine R - GuruFocus
US FDA approves Amneal’s self-administered migraine treatment - 1470 & 100.3 WMBD
FDA Greenlights Amneal's (AMRX) Innovative Migraine Treatment | AMRX Stock News - GuruFocus
Amneal Pharmaceuticals' Brekiya Approved by FDA - marketscreener.com
Amneal rises after US FDA greenlights self-administered migraine treatment - TradingView
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in Adults - The Manila Times
US FDA approves Amneal's migraine treatment - marketscreener.com
Amneal Receives U.S. FDA Approval for Brekiya® - GlobeNewswire
Breakthrough: First At-Home Injectable Migraine Treatment Gets FDA Green LightWhat Makes It Different - Stock Titan
This Insider Has Just Sold Shares In Amneal Pharmaceuticals - simplywall.st
Amneal Pharmaceuticals (NASDAQ:AMRX) Stock Rating Lowered by StockNews.com - Defense World
Director John Kiely Sells 50,000 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus
Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing - insights.citeline.com
Key Trends Shaping the Future of Filgrastim Biosimilars Market: Amneal Pharmaceuticals' Fylnetra Marks A Ne... - WhaTech
Are Options Traders Betting on a Big Move in Amneal Pharmaceuticals Stock? - MSN
Amneal Announces Submission of New Drug Application to the U.S. FDA for IPX203 for the Treatment of Parkinson’s Disease - Business Wire
Amneal Pharmaceuticals to add 200 jobs at its Brookhaven factory - Newsday
Does Amneal (AMRX) Have the Potential to Rally 54.16% as Wall Street Analysts Expect? - Yahoo Finance
Amneal and Apiject join forces to boost US pharmaceutical manufacturing - World Pharmaceutical Frontiers
Decoding Amneal Pharmaceuticals Inc (AMRX): A Strategic SWOT Ins - GuruFocus
Amneal Pharmaceuticals Approves Key Proposals at Annual Meeting - TipRanks
Here is Why Growth Investors Should Buy Amneal (AMRX) Now - Yahoo Finance
Are Options Traders Betting On A Big Move In Amneal Pharmaceuticals Stock? - Barchart.com
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal - GlobeNewswire
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced ... - Bluefield Daily Telegraph
Finanzdaten der Amneal Pharmaceuticals Inc-Aktie (AMRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
18.36%
0.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):